| 货号 | MAB741 |
| 别名 | Activation B7-2 antigen; B70; B7-2 antigen; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; CD28LG2B7-2 antigen); CD86 antigen; CD86 molecule; CD86; CTLA-4 counter-receptor B7.2; FUN-1; LAB72; MGC34413; T-lymphocyte activation antigen CD86 |
| 反应种属 | Mouse |
| 应用 | Western Blot(1 µg/mL) Flow Cytometry(2.5 µg/106cells) |
| 目标/特异性 | Detects mouse B7‑2/CD86 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse B7-1, recombinant human (rh) B7-1 or rhB7-2 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Flow Cytometry: 2.5 µg/106cells Neutralization: Measured by its ability to neutralize B7‑2/CD86-induced IL‑2 secretion in the Jurkat human acute T cell leukemia cell line. Linsley, P. et al. (1990) Proc. Natl. Acad. Sci. 87:5031. The Neutralization Dose (ND50) is typically 0.05-0.25 µg/mL in the presence of 0.5 µg/mL Recombinant Mouse B7‑2/CD86 Fc Chimera and 10 µg/mL PHA. |
| 来源 | Monoclonal Rat IgG2A Clone # GL1 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 942 (Human); 12524 (Mouse); 56822 (Rat) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. | |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | LPS-activated mouse B cells |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant costimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20‑100 fold higher affinity than CD28 and is involved in the down‑regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up‑regulated through interferon gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. Mouse B7-2 is a 309 amino acid (aa) protein containing a putative 23 aa signal peptide, a 221 aa extracellular domain, a 21 aa transmembrane domain, and a 44 aa cytoplasmic domain. Mouse B7-2 and B7-1 share 28% amino acid identity. Mouse and human B7-2 share 50% amino acid identity. However, it has been observed that both human and mouse B7‑1 and B7‑2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
IL‑2 secretion Induced by B7‑2/CD86 and Neutralization by Mouse B7‑2/CD86 Antibody. Recombinant Mouse B7‑2/CD86 Fc Chimera (Catalog # 741-B2) co-stimulates IL‑2 secretion in the Jurkat human acute T cell leukemia cell line in the presence of PHA in a dose-dependent manner (orange line), as measured by the Human IL‑2 Quantikine ELISA Kit (Catalog # D2050). IL‑2 secretion elicited by Recombinant Mouse B7‑2/CD86 Fc Chimera (0.5 µg/mL) and PHA (10 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse B7‑2/CD86 Monoclonal Antibody (Catalog # MAB741). The ND50 is typically 0.05‑0.25 µg/mL. |
